Nuvalent (NUVL) Income from Continuing Operations (2020 - 2026)
Nuvalent's (NUVL) quarterly Income from Continuing Operations came in at 109279000.0 in Q1 2026, down 29.2% YoY from 154346436.97 in Q1 2025, and down 277.94% on a QoQ basis from 28914000.0 in Q4 2025.
Nuvalent (NUVL) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Income from Continuing Operations data on file, last reported at 109279000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 29.2% year-over-year to 109279000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 360283000.0 (down 19.75% YoY) and the FY2025 annual result came in at 335586000.0, down 28.7% from the prior year.
- Income from Continuing Operations eased to 109279000.0 in Q1 2026, from 28914000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 18571000.0 in Q1 2022 to a low of 122437000.0 in Q3 2025.
- A 5-year average of 54003235.29 and a median of 38292000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 201.38% — and 2025, when it soared 61.33%.
- Tracing NUVL's Income from Continuing Operations over 5 years: stood at 27462000.0 in 2022, then sank by 39.44% to 38292000.0 in 2023, then sank by 95.24% to 74763000.0 in 2024, then soared by 61.33% to 28914000.0 in 2025, then slumped by 277.94% to 109279000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 109279000.0 (Q1 2026), 28914000.0 (Q4 2025), and 122437000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | -109.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -109.28 Mn |
| Dec 31, 2025 | -28.91 Mn |
| Sep 30, 2025 | -122.44 Mn |
| Jun 30, 2025 | -99.65 Mn |
| Mar 31, 2025 | -84.58 Mn |
| Dec 31, 2024 | -74.76 Mn |
| Sep 30, 2024 | -84.35 Mn |
| Jun 30, 2024 | -57.17 Mn |
| Mar 31, 2024 | -44.48 Mn |
| Dec 31, 2023 | -38.29 Mn |
| Sep 30, 2023 | -33.65 Mn |
| Jun 30, 2023 | -29.09 Mn |
| Mar 31, 2023 | -25.19 Mn |
| Dec 31, 2022 | -27.46 Mn |
| Sep 30, 2022 | -20.58 Mn |
| Jun 30, 2022 | -19.60 Mn |
| Mar 31, 2022 | -18.57 Mn |
| Dec 31, 2021 | -40.78 Mn |
| Sep 30, 2021 | -12.43 Mn |
| Jun 30, 2021 | -9.85 Mn |